Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.
Cost of illness
Direct cost
Indirect cost
Lower respiratory tract infections
Respiratory syncytial virus
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Feb 2023
06 Feb 2023
Historique:
received:
08
09
2022
accepted:
23
01
2023
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
9
2
2023
Statut:
epublish
Résumé
Little information is available on the costs of respiratory syncytial virus (RSV) in Vietnam or other low- and middle-income countries. Our study estimated the costs of LRTIs associated with RSV infection among children in southern Vietnam. We conducted a prospective cohort study evaluating household and societal costs associated with LRTIs stratified by RSV status and severity among children under 2 years old who sought care at a major pediatric referral hospital in southern Vietnam. Enrollment periods were September 2019-December 2019, October 2020-June 2021 and October 2021-December 2021. RSV status was confirmed by a validated RT-PCR assay. RSV rapid detection antigen (RDA) test performance was also evaluated. Data on resource utilization, direct medical and non-medical costs, and indirect costs were collected from billing records and supplemented by patient-level questionnaires. All costs are reported in 2022 US dollars. 536 children were enrolled in the study, with a median age of 7 months (interquartile range [IQR] 3-12). This included 210 (39.2%) children from the outpatient department, 318 children (59.3%) from the inpatient respiratory department (RD), and 8 children (1.5%) from the intensive care unit (ICU). Nearly 20% (105/536) were RSV positive: 3.9 percent (21/536) from the outpatient department, 15.7% (84/536) from the RD, and none from the ICU. The median total cost associated with LRTI per patient was US$52 (IQR 32-86) for outpatients and US$184 (IQR 109-287) for RD inpatients. For RSV-associated LRTIs, the median total cost per infection episode per patient was US$52 (IQR 32-85) for outpatients and US$165 (IQR 95-249) for RD inpatients. Total out-of-pocket costs of one non-ICU admission of RSV-associated LRTI ranged from 32%-70% of the monthly minimum wage per person (US$160) in Ho Chi Minh City. The sensitivity and the specificity of RSV RDA test were 88.2% (95% CI 63.6-98.5%) and 100% (95% CI 93.3-100%), respectively. These are the first data reporting the substantial economic burden of RSV-associated illness in young children in Vietnam. This study informs policymakers in planning health care resources and highlights the urgency of RSV disease prevention.
Sections du résumé
BACKGROUND
BACKGROUND
Little information is available on the costs of respiratory syncytial virus (RSV) in Vietnam or other low- and middle-income countries. Our study estimated the costs of LRTIs associated with RSV infection among children in southern Vietnam.
METHODS
METHODS
We conducted a prospective cohort study evaluating household and societal costs associated with LRTIs stratified by RSV status and severity among children under 2 years old who sought care at a major pediatric referral hospital in southern Vietnam. Enrollment periods were September 2019-December 2019, October 2020-June 2021 and October 2021-December 2021. RSV status was confirmed by a validated RT-PCR assay. RSV rapid detection antigen (RDA) test performance was also evaluated. Data on resource utilization, direct medical and non-medical costs, and indirect costs were collected from billing records and supplemented by patient-level questionnaires. All costs are reported in 2022 US dollars.
RESULTS
RESULTS
536 children were enrolled in the study, with a median age of 7 months (interquartile range [IQR] 3-12). This included 210 (39.2%) children from the outpatient department, 318 children (59.3%) from the inpatient respiratory department (RD), and 8 children (1.5%) from the intensive care unit (ICU). Nearly 20% (105/536) were RSV positive: 3.9 percent (21/536) from the outpatient department, 15.7% (84/536) from the RD, and none from the ICU. The median total cost associated with LRTI per patient was US$52 (IQR 32-86) for outpatients and US$184 (IQR 109-287) for RD inpatients. For RSV-associated LRTIs, the median total cost per infection episode per patient was US$52 (IQR 32-85) for outpatients and US$165 (IQR 95-249) for RD inpatients. Total out-of-pocket costs of one non-ICU admission of RSV-associated LRTI ranged from 32%-70% of the monthly minimum wage per person (US$160) in Ho Chi Minh City. The sensitivity and the specificity of RSV RDA test were 88.2% (95% CI 63.6-98.5%) and 100% (95% CI 93.3-100%), respectively.
CONCLUSION
CONCLUSIONS
These are the first data reporting the substantial economic burden of RSV-associated illness in young children in Vietnam. This study informs policymakers in planning health care resources and highlights the urgency of RSV disease prevention.
Identifiants
pubmed: 36747128
doi: 10.1186/s12879-023-08024-2
pii: 10.1186/s12879-023-08024-2
pmc: PMC9901829
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Subventions
Organisme : Bill and Melinda Gates Foundation
ID : INV-007610
Informations de copyright
© 2023. The Author(s).
Références
Pediatr Infect Dis J. 2010 Jan;29(1):75-7
pubmed: 19907358
Vaccine. 2021 Apr 15;39(16):2303-2310
pubmed: 33745731
PLoS One. 2016 Aug 08;11(8):e0160606
pubmed: 27500954
Lancet. 2022 May 28;399(10340):2047-2064
pubmed: 35598608
Influenza Other Respir Viruses. 2015 May;9(3):110-9
pubmed: 25702707
N Engl J Med. 2022 Mar 3;386(9):837-846
pubmed: 35235726
Early Hum Dev. 2015 Sep;91(9):541-6
pubmed: 26186560
J Infect Dis. 2020 Oct 7;222(Suppl 7):S680-S687
pubmed: 32227101
Cochrane Database Syst Rev. 2019 Jan 02;1:CD010277
pubmed: 30601584
Front Pediatr. 2022 Nov 09;10:1033125
pubmed: 36440349
Arch Dis Child. 2022 Apr;107(4):359-364
pubmed: 34526293
Trop Med Int Health. 2014 Nov;19(11):1321-7
pubmed: 25130978
N Engl J Med. 2022 Mar 3;386(9):892-894
pubmed: 35235733
Expert Rev Respir Med. 2015;9(6):779-99
pubmed: 26457970
Pediatr Infect Dis J. 2014 Apr;33(4):337-41
pubmed: 24088730
J Virol Methods. 2012 Jan;179(1):250-5
pubmed: 22119628
Vaccine. 2016 Jan 4;34(2):190-197
pubmed: 26100926
J Health Popul Nutr. 2010 Oct;28(5):436-42
pubmed: 20941894
Pediatrics. 2014 Nov;134(5):e1474-502
pubmed: 25349312
BMJ Open. 2018 Jun 8;8(6):e019795
pubmed: 29884695
PLoS One. 2011 Mar 24;6(3):e18176
pubmed: 21455313
Psychometrika. 1947 Jun;12(2):153-7
pubmed: 20254758
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Pediatr Infect Dis J. 2015 Apr;34(4):361-70
pubmed: 25674708
BMC Med. 2020 Apr 6;18(1):82
pubmed: 32248817
Pediatr Infect Dis J. 2018 Sep;37(9):886-892
pubmed: 29373476
Pediatr Infect Dis J. 2011 Jan;30(1):11-8
pubmed: 20686433